Barlogie, B., Pineda-Roman, M., van Rhee, F., Haessler, J., Anaissie, E., Hollmig, K., . . . Crowley, J. (2008). Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. American Society of Hematology.
Chicago Stili AlıntıBarlogie, Bart, et al. Thalidomide Arm of Total Therapy 2 Improves Complete Remission Duration and Survival in Myeloma Patients With Metaphase Cytogenetic Abnormalities. American Society of Hematology, 2008.
MLA AlıntıBarlogie, Bart, et al. Thalidomide Arm of Total Therapy 2 Improves Complete Remission Duration and Survival in Myeloma Patients With Metaphase Cytogenetic Abnormalities. American Society of Hematology, 2008.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..